Grifols S.A. Net Assets
Grifols S.A. net assets. Based on the latest financial reports, Grifols S.A. (GRF) has net assets worth €7.60 Billion EUR (≈ $8.88 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€19.77 Billion ≈ $23.11 Billion USD) and total liabilities (€12.17 Billion ≈ $14.23 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Grifols S.A. (GRF) net asset quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.60 Billion |
| % of Total Assets | 38.44% |
| Annual Growth Rate | 30.35% |
| 5-Year Change | 28.08% |
| 10-Year Change | 160.71% |
| Growth Volatility | 123.39 |
Net Assets of Grifols S.A. (2005–2024)
Net assets of Grifols S.A. from 2005 to 2024. This chart illustrates how Grifols S.A.'s net assets have evolved over time, based on quarterly financial data. Also explore Grifols S.A. (GRF) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for Grifols S.A. (2005–2024)
The table below shows the annual net assets of Grifols S.A. from 2005 to 2024. For live market cap and overall valuation, see GRF market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €8.61 Billion ≈ $10.06 Billion |
+7.96% |
| 2023-12-31 | €7.97 Billion ≈ $9.32 Billion |
-5.74% |
| 2022-12-31 | €8.46 Billion ≈ $9.89 Billion |
+3.81% |
| 2021-12-31 | €8.15 Billion ≈ $9.52 Billion |
+21.23% |
| 2020-12-31 | €6.72 Billion ≈ $7.86 Billion |
-1.84% |
| 2019-12-31 | €6.85 Billion ≈ $8.00 Billion |
+45.76% |
| 2018-12-31 | €4.70 Billion ≈ $5.49 Billion |
+29.24% |
| 2017-12-31 | €3.63 Billion ≈ $4.25 Billion |
-2.52% |
| 2016-12-31 | €3.73 Billion ≈ $4.36 Billion |
+12.92% |
| 2015-12-31 | €3.30 Billion ≈ $3.86 Billion |
+23.98% |
| 2014-12-31 | €2.66 Billion ≈ $3.11 Billion |
+26.37% |
| 2013-12-31 | €2.11 Billion ≈ $2.46 Billion |
+12.04% |
| 2012-12-31 | €1.88 Billion ≈ $2.20 Billion |
+12.96% |
| 2011-12-31 | €1.66 Billion ≈ $1.95 Billion |
+135.37% |
| 2010-12-31 | €707.39 Million ≈ $827.01 Million |
+22.27% |
| 2009-12-31 | €578.53 Million ≈ $676.36 Million |
+20.21% |
| 2008-12-31 | €481.28 Million ≈ $562.67 Million |
+25.28% |
| 2007-12-31 | €384.17 Million ≈ $449.13 Million |
+4.29% |
| 2006-12-31 | €368.35 Million ≈ $430.64 Million |
+558.39% |
| 2005-12-31 | €55.95 Million ≈ $65.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Grifols S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 704.8% over the analyzed period, indicating profitable operations and earnings retention.
Grifols S.A. Net Assets Breakdown (December 2024)
Grifols S.A. net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €205.68 Million | 3.50% |
| Common Stock | €119.60 Million | 2.03% |
| Other Comprehensive Income | €4.78 Billion | 81.28% |
| Other Components | €776.28 Million | 13.19% |
| Total Equity | €5.88 Billion | 100.00% |
Grifols S.A. Competitors by Market Cap
The table below lists competitors of Grifols S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shan Dong Sun Paper Industry Joint Stock Co Ltd
SHE:002078
|
$5.28 Billion |
|
Ringcentral Inc
NYSE:RNG
|
$5.28 Billion |
|
Erasca Inc
NASDAQ:ERAS
|
$5.29 Billion |
|
Versant Media Group, Inc.
NASDAQ:VSNTV
|
$5.29 Billion |
|
Linde India Limited
NSE:LINDEINDIA
|
$5.28 Billion |
|
ACI Worldwide Inc
NASDAQ:ACIW
|
$5.27 Billion |
|
Rumo S.A
SA:RAIL3
|
$5.27 Billion |
|
West Fraser Timber Co Ltd
TO:WFG
|
$5.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Grifols S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,827,166,000 to 5,883,727,000, a change of 56,561,000 (1.0%).
- Net income of 156,920,000 contributed positively to equity growth.
- Dividend payments of 962,000 reduced retained earnings.
- Other comprehensive income decreased equity by 108,105,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €156.92 Million | +2.67% |
| Dividends Paid | €962.00K | -0.02% |
| Other Comprehensive Income | €-108.11 Million | -1.84% |
| Other Changes | €8.71 Million | +0.15% |
| Total Change | €- | 0.97% |
Book Value vs Market Value Analysis
This analysis compares Grifols S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 80.74x to 1.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €0.13 | €10.70 | x |
| 2006-12-31 | €0.86 | €10.70 | x |
| 2007-12-31 | €0.78 | €10.70 | x |
| 2008-12-31 | €0.99 | €10.70 | x |
| 2009-12-31 | €1.17 | €10.70 | x |
| 2010-12-31 | €1.57 | €10.70 | x |
| 2011-12-31 | €2.52 | €10.70 | x |
| 2012-12-31 | €2.74 | €10.70 | x |
| 2013-12-31 | €3.09 | €10.70 | x |
| 2014-12-31 | €3.88 | €10.70 | x |
| 2015-12-31 | €4.81 | €10.70 | x |
| 2016-12-31 | €5.44 | €10.70 | x |
| 2017-12-31 | €5.30 | €10.70 | x |
| 2018-12-31 | €6.17 | €10.70 | x |
| 2019-12-31 | €7.04 | €10.70 | x |
| 2020-12-31 | €7.46 | €10.70 | x |
| 2021-12-31 | €8.98 | €10.70 | x |
| 2022-12-31 | €9.04 | €10.70 | x |
| 2023-12-31 | €8.58 | €10.70 | x |
| 2024-12-31 | €8.65 | €10.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Grifols S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.18%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 3.64x
- Recent ROE (2.67%) is below the historical average (14.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 45.78% | 4.87% | 0.64x | 14.72x | €19.97 Million |
| 2006 | 12.34% | 7.00% | 0.71x | 2.48x | €8.60 Million |
| 2007 | 22.91% | 12.48% | 0.75x | 2.45x | €49.46 Million |
| 2008 | 25.36% | 14.95% | 0.69x | 2.46x | €73.73 Million |
| 2009 | 26.13% | 16.20% | 0.55x | 2.93x | €91.33 Million |
| 2010 | 16.67% | 11.66% | 0.52x | 2.73x | €46.21 Million |
| 2011 | 3.03% | 2.80% | 0.31x | 3.49x | €-115.94 Million |
| 2012 | 13.68% | 9.79% | 0.47x | 3.00x | €69.01 Million |
| 2013 | 16.44% | 12.60% | 0.47x | 2.78x | €135.42 Million |
| 2014 | 17.69% | 14.01% | 0.40x | 3.18x | €204.44 Million |
| 2015 | 16.14% | 13.52% | 0.41x | 2.91x | €202.52 Million |
| 2016 | 14.66% | 13.47% | 0.40x | 2.72x | €173.31 Million |
| 2017 | 18.26% | 15.35% | 0.40x | 3.01x | €299.79 Million |
| 2018 | 14.12% | 13.30% | 0.36x | 2.95x | €174.09 Million |
| 2019 | 12.96% | 12.26% | 0.33x | 3.22x | €142.93 Million |
| 2020 | 12.11% | 11.58% | 0.35x | 2.99x | €107.71 Million |
| 2021 | 4.35% | 5.38% | 0.26x | 3.15x | €-344.34 Million |
| 2022 | 3.40% | 3.43% | 0.28x | 3.51x | €-404.71 Million |
| 2023 | 1.02% | 0.90% | 0.31x | 3.68x | €-523.40 Million |
| 2024 | 2.67% | 2.18% | 0.34x | 3.64x | €-431.45 Million |
Industry Comparison
This section compares Grifols S.A.'s net assets metrics with peer companies in the Drug Manufacturers - General industry.
No peer company data available for comparison.
About Grifols S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more